33results about "Inorganic active ingredients" patented technology

Provided herein are pharmaceutically acceptable sodium nitrite and pharmaceutical compositions thereof. Also provided herein are methods for determining the total non-volatile organic carbon in a sodium nitrite-containing sample. Further provided herein are methods for producing pharmaceutically acceptable sodium nitrite. Still further provided herein are methods of treatment comprising the administration of pharmaceutically acceptable sodium nitrite.

The invention discloses a Chinese material medical preparation, which cures orthopedic disorders and is made by olibanum, myrrh, ground beeltle, natural copper, pseudoginseng, safflower, knotweed, peach seed, eucommia bark, angelica and pawpaw through Chinese traditional medicine processing technique. The invention mainly cure the orthopaedics diseases of lumbar and shoulder projection, hyperosteogeny, cervical spondylosis, periarthritis humeroscapularis, arthritis, rheumatoid arthritis, old fracture and tenosynovitis, etc. The invention uses pure Chinese medicinal herb to make chemical preparation, has small toxic and side effect and obvious healing effect, and addresses both the symptoms and root causes, moreover, the clinical symptoms are rapid to eliminate, and have no rebound phenomenon after healing.

An aqueous precipitation process for the preparation of particles comprising primarily silver sulfate, comprising reacting an aqueous soluble silver salt and an aqueous soluble source of inorganic sulfate ion in an agitated precipitation reactor vessel and precipitating particles comprising primarily silver sulfate, wherein the reaction and precipitation are performed in the presence of an aqueous soluble carboxylic acid additive or salt thereof, the amount of additive being a minor molar percentage, relative to the molar amount of silver sulfate precipitated, and effective to result in precipitation of particles comprising primarily silver sulfate having a mean grain-size of less than 70 micrometers.

The presently disclosed subject matter relates generally to the fields of molecular biology and medicine. More particularly, it concerns methods involving the use of GSK3 inhibitors in combination with radiation therapies. In some embodiments, administration of a GSK3 inhibitor to a subject results in an amelioration of cognitive decline, toxicity to vascular endothelial cells, and/or neuron death associated with radiation therapy alone.

The present invention relates to methods of treating cancer, in which a CXCR4 inhibitor such as X4P-001 or a pharmaceutically acceptable salt thereof or pharmaceutical composition thereof is administered in combination with an additional therapeutic agent, such as an immune checkpoint inhibitor. The methods demonstrate surprising results, including regression of disease, with comparatively little toxicity.

The invention discloses an oxygen-fluorine liposome microbubble therapeutic agent which consists of microbubbles, and oxygen and at least one perfluocarbon existing in the microbubbles, wherein the gas nucleus takes oxygen as a principle component and takes perfluocarbon as an auxiliary component, and the microbubble mainly consists of phospholipid and polyethylene glycol derivative. According to the oxygen-fluorine liposome microbubble therapeutic agent, oxygen can be controlled to be released in a human body through veins delivery and targeted hypoxia tissue under ultrasound wave irradiation, the hypoxia disease is treated, and the therapeutic agent serves as a contrast agent used for ultrasonic enhanced imaging. Therefore, the microbubble is a developing agent and an oxygenating therapeutic agent.

The invention discloses compound ozone oil and a preparation method. The compound ozone oil is prepared from raw materials, namely 80-90 parts of camellia-seed oil, 10-30 parts of cnidium monnieri volatile oil and 5-15 parts of rhizoma atractylodis volatile oil, wherein the camellia-seed oil is subjected to ozone immobilization reaction, and the ozone oil of which the ozone content is 35-65g/L can be prepared. As the camellia-seed oil is adopted as base oil to prepare the ozone oil, and with the combination of the cnidium monnieri volatile oil and the rhizoma atractylodis volatile oil, the compound ozone oil is relatively wide in treatment field and relatively ideal in treatment effect. In addition, the compound ozone oil disclosed by the invention is scientific and reasonable in preparation process, and ozone can be stably immobilized without being volatilized and can be very well compounded with other traditional Chinese medicinal volatile oil, therefore, a synergic treatment function can be achieved.

The invention discloses a preparation method of aqueous-film-coated enterosoluble zinc oxide micro-pills. The aqueous-film-coated enterosoluble zinc oxide micro-pills are composed of the following ingredients: in per 100% by mass, 40-85% of zinc oxide, and 15-60% of auxiliary materials; (b), enterosoluble film coating layers of which the weight accounts for 5-30%, preferably 10-20%, of the weight of the zinc oxide micro-pill cores; and (c), particle size of the final zinc oxide micro-pills is 10-100 meshes, preferably 40-60 meshes. The aqueous-film-coated enterosoluble zinc oxide micro-pills are non-soluble in the stomach but soluble in the intestinal tract; and solution rate of the zinc oxide micro-pills in the intestinal tract is adjustable from 30 minutes to 3 hours, and thus, the zinc oxide can be uniformly dispersed in the intestinal tract. The aqueous-film-coated enterosoluble zinc oxide micro-pills have characteristics of common enterosoluble zinc oxide, namely the effects of preventing diarrhea and low dosage; moreover, usage of organic solvents in preparation processes of the enterosoluble zinc oxide is also avoided so that the preparation method of the aqueous-film-coated enterosoluble zinc oxide micro-pills is environmentally friendly, free of potential safety hazard, and capable of greatly improving economic benefits.

The invention relates to method for stimulating hair growth and regeneration in a mammal in need thereof, which comprises a step of applying to the skin of said mammal an effective amount of water comprising from about 99.760 to about 99.999% of light isotopologue ¹H₂¹⁶0 and up to 100% of residual isotopologues ¹H₂¹⁷0, ¹H₂¹⁸0, ¹H₂H¹⁶0 ¹H₂H¹⁷0, ¹H₂H¹⁸0, ²H₂¹⁶0, ²H₂¹⁷0, and ²H₂¹⁸0. Preferably, the mammal is a human.

The invention relates to liquid oxygen in-situ forming gel and a preparation method and application thereof. The liquid oxygen in-situ forming gel comprises the following materials in percentage by weight: 10 to 40 percent of poloxamer, 0.001 to 1 percent of nano silver and 59 to 89.4 percent of solvent. The preparation method comprises the following steps of: adding water into the poloxamer, stirring uniformly, swelling and defoaming to obtain a medicinal base material, adding the nano silver into the base material and stirring uniformly. The liquid oxygen in-situ forming gel can be used for treating vaginitis, rhinitis, otitis and skin tinea diseases. The poloxamer is taken as a temperature sensitive material, and the in-situ forming gel can reside in a human body for more than 20h, so that a medicine taking frequency can be reduced, the compliance of a patient can be improved, a pharmacological treatment effect can be enhanced, and toxic and side effects can be lowered.

The invention relates to a mineral substance crystal for regulating uric acid, which is prepared from the following components in parts by weight: 25-45 parts of red marble, 30-50 parts of Longjiang stone and 15-35 parts of celestite. Compared with the prior art, the equilibrium liquid formed by soaking the mineral substance crystal provided by the invention has the advantages of good effect, no toxic side effect and the like, is convenient and simple in use, and can not injure the kidney, intestine and stomach.

The invention discloses a metal ion copper-doped polyaminopyrrole composite nano-particle diagnosis and treatment reagent as well as a preparation method and an application thereof in preparing an efficient tumor regeneration-inhibiting medicine or preparing a tumor diagnosis and treatment reagent, belonging to the technical field of functional materials. The preparation method comprises the following steps: dissolving an aminopyrrole monomer in water; adding cooper salt and sufficiently dissolving; adding an aqueous solution of surfactant polyvinyl alcohol; stirring uniformly and adding iron salt; stirring uniformly and reacting for 6-24 hours at room temperature to obtain a composite nano-particle solution; and performing centrifugal separation to obtain copper ion-doped polyaminopyrrole composite nano particles. The metal ion copper-doped polyaminopyrrole composite nano particles prepared in the invention integrate multiple functions such as photothermal treatment, chemotherapy and nuclear magnetic imaging radiography, the potential of a diagnosis and treatment platform can be sufficiently played in tumor diagnosis and treatment, and an application in the field of cancer diagnosis and treatment is realized.

Disclosed are methods of selectively delivering a medicant to an abnormal brain region and/or to a malignant tumor in a mammalian subject, including a human. A medicant is administered simultaneously or substantially simultaneously with a potassium channel activator (other than bradykinin or a bradykinin analog), such as an activator of soluble guanylyl cyclase (e.g., nitric oxide or a nitric oxide donor) or an activator of cyclic GMP-dependent protein kinase, whereby the medicant is delivered selectively to the cells of the abnormal brain region and/or to the tumor, compared to normal tissues. Thus, among the disclosures is a method of treating a malignant tumor in a human subject. Also disclosed are pharmaceutical compositions that combine a potassium channel activator together with a medicant and a kit for enhancing the delivery of a medicant to an abnormal brain region and/or to a malignant tumor.

The invention discloses a compound preparation for treating skin diseases of animals, and a preparation method of the compound preparation for treating skin diseases of animals, relates to the technical field of veterinary medicines, and solves the problem that outdoor applying is inconvenient. The compound preparation comprises the following components in parts by weight: 2 parts of ozone oil, 1.5 parts of olive oil, 1.5 parts of peppermint oil, 2 parts of matrine, 2 parts of camphor, 1 part of borneol, 3 parts of mint, 2 parts of common cnidium fruits, 2 parts of lithargyrum, 2 parts of Chinese galls, 1 part of fructus evodiae, 2 parts of dried ginger and 2 parts of herba violae. The preparation method of the compound preparation comprises the following steps of taking the ozone oil, thecamphor, the olive oil, the peppermint oil, the matrine, the borneol and the dried ginger for standby application; and picking the mint, the common cnidium fruits, the lithargyrum, the Chinese galls,the fructus evodiae and the herba violae, respectively removing impurities, performing thorough cleaning, performing cutting into segments or slices, and performing drying by airing. According to thecompound preparation and the preparation method thereof disclosed by the invention, infected parts of animals are slightly cleaned with a hydrogen peroxide solution and wiped and dried or not scoured, the compound preparation is applied and sprayed onto the infected parts of the animals, and the compound preparation is simple to prepare and convenient to use.

The invention discloses application of a DNAJC19 gene as a target in preparation of a drug for treating non-small cell lung cancer (NSCLC). The drug is used for inhibiting DNAJC19 gene expression, andcomprises an inhibitor which is used as an active component and is used for inhibiting DNAJC19 gene expression, and pharmaceutically acceptable auxiliary components of the inhibitor; and the inhibitor is at least one of shRNA, siRNA, dsRNA, miRNA, cDNA, antisense RNA/DNA, a low-molecular compound, a peptide, an antibody and the like. The invention finds that a DNAJC19/HSPA9/AKT1 signal path participates in proliferation and migration of NSCLC cells and verifies that the invasion, migration and growth capability of NSCLC can be effectively reduced by inhibiting the expression of DNAJC19, and the growth and metastasis of tumor cells are greatly weakened, so that DNAJC19 becomes a treatment target of NSCLC patients.

The invention relates to a traditional Chinese medical pill for treating bronchitis, and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medical pill is prepared through the steps that crude drugs such as white poria cocos, roasted radix peucedani, roasted rhizoma cynanchi stauntonii, radix scutellariae, fructus viticis and pumex are ground to pass througha 100-mesh sieve and dried after being weighed, heated and disinfected, and refined honey is added into a product at the mass ratio of 1 to 1, so that a big honey pill is obtained. The traditional Chinese medical pill overcomes defects of existing drugs for treating bronchitis, the prescription is clear in rules of treatment, achieves reasonable medicine compatibility, has the efficacy of tonifying Qi and warming the middle warmer, expelling wind and removing cold, reducing phlegm and killing acarus and the like, has a good treatment effect, can take effect rapidly, is convenient to take, andis safe and reliable, the raw materials are natural and easy to get, and the pill has the effect of treating both symptoms and root causes on bronchitis.

The method of synthesizing antimicrobial silver nanoparticles using pigeon dung includes collecting pigeon dung and suspending the pigeon dung in water to produce a pigeon dung aqueous extract, filtering the pigeon dung aqueous extract, adding a solution including a silver source to the pigeon dung aqueous extract to produce a mixture, and resting the mixture to allow silver nanoparticles to form. In an embodiment the antimicrobial pigeon dung nanoparticles may be incorporated in a pharmaceutical composition.

The invention provides application of anwuligan or a pharmaceutical composition thereof in colorectal cancer treatment, belongs to the field of colorectal cancer treatment, and solves the problems that an existing medicine cannot effectively inhibit M2 type polarization of macrophages and is not ideal in chemotherapy effect. Wherein the anwuligan can be independently used, or the anwuligan can be combined with an existing anti-cancer drug such as cis-platinum or 5-fluorouracil for use. The anwuligan can inhibit M2 type polarization of macrophages and enhance chemosensitivity of colorectal cancer cells. The anwuligan is used before the cis-platinum, or the medicine A containing the anwuligan is used before the medicine B containing the cis-platinum, the chemosensitivity of colorectal cancer cells to the cis-platinum can be reduced, the treatment effect of the cis-platinum on the colorectal cancer can be effectively improved by taking the medicine containing the cis-platinum, and the medicine has a good clinical medication development prospect.

The invention discloses a precious metal anti-cancer nano material and a preparation method and application thereof.The preparation method comprises the steps that a chloroauric acid aqueous solution, a chloroplatinic acid aqueous solution and a copper chloride aqueous solution are evenly mixed, an ascorbic acid aqueous solution is added, heating is conducted for 1-4 h at the temperature of 30-60 DEG C, a product is centrifugally washed, and the precious metal anti-cancer nano material is obtained. The precious metal anti-cancer nano material with the face-centered cubic structure can be obtained. According to the preparation method of the precious metal anti-cancer nano material, the problem that in the prior art, the preparation conditions for preparing the precious metal-transition metal alloy nano material are harsh and tedious is solved. And the reaction is carried out in a water phase without adding an organic solvent or a surfactant, so that the prepared precious metal anticancer nano material can be prevented from being polluted by reagents.

The present invention relates to a method and a unit for preparing a solid material for storing ozone, said method comprising contacting cyclodextrins and/or derivatives of cyclodextrins in solid form with a gas comprising ozone, by means of which a solid material for storing ozone is obtained. The present invention also relates to the material thus prepared and to the uses thereof.

The invention provides a gold nanostar for identifying and degrading PD-L1 on the surfaces of prostate cancer cells as well as a preparation method and application of the gold nanostar, and relates to the technical field of biological medicines. According to the invention, PD-L1 binding peptide, autophagy induction peptide and the gold nanostar are utilized for the first time, and a nano-particle capable of identifying and efficiently degrading PD-L1 on the surfaces of prostate cancer cells are successfully constructed. According to the method, the PD-L1 binding peptide and the autophagy induction peptide are grafted to the surface of the gold nanostar, and PD-L1 is recognized and degraded through a nanodevice, so immune escape of prostate cells is inhibited, anti-tumor immunity is enhanced, the progress of prostate cancer is inhibited, and the purpose of treating prostate cancer is achieved.

Methods of inhibiting Barrett's esophagus and/or adenocarcinoma in a subject are provided. In a particular embodiment, the method comprises administering at least one composition comprising at least one zinc compound and at least one pharmaceutically acceptable carrier to the esophagus of the subject. The zinc may be a pharmaceutically acceptable salt of zinc, such as zinc gluconate. The zinc may be administered, for example, orally, topically, or by an implantable medical device. In a particular embodiment, the methods further comprise administering at least one analgesic, anesthetic, or other therapeutic agent or therapy for the treatment of Barrett's esophagus. The method may further comprise monitoring the progression of Barrett's esophagus in the subject.